AbbVie Inc. $ABBV Stock Holdings Raised by Boston Partners

Boston Partners increased its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 0.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,827,961 shares of the company’s stock after buying an additional 43,645 shares during the quarter. AbbVie makes up 1.1% of Boston Partners’ holdings, making the stock its 9th biggest position. Boston Partners owned about 0.27% of AbbVie worth $1,264,123,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. State Street Corp grew its holdings in AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares during the period. Fisher Asset Management LLC increased its position in AbbVie by 252.6% during the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock worth $8,760,498,000 after buying an additional 23,991,451 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after buying an additional 106,091 shares during the last quarter. Legal & General Group Plc bought a new stake in AbbVie in the second quarter valued at approximately $2,905,952,000. Finally, Deutsche Bank AG raised its stake in AbbVie by 13.0% in the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after buying an additional 1,241,587 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie News Summary

These are some of the ABBV news items that stood out recently:

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Guggenheim raised their price objective on AbbVie from $288.00 to $322.00 and gave the company a “buy” rating in a research report on Monday, November 2nd. UBS Group boosted their target price on AbbVie from $275.00 to $295.00 and gave the stock a “neutral” rating in a report on Monday, November 2nd. BMO Capital Markets set a $315.00 target price on AbbVie in a report on Wednesday, November 4th. Morgan Stanley increased their price target on AbbVie from $310.00 to $346.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. Finally, Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $299.62.

Get Our Latest Report on AbbVie

Insider Transactions at AbbVie

In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the company’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the transaction, the executive vice president directly owned 83,171 shares of the company’s stock, valued at $24,419,005.60. This represents a 32.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

AbbVie Stock Performance

Shares of ABBV opened at $285.92 on Thursday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $302.93. The firm has a market cap of $505.39 billion, a P/E ratio of 22.82, a price-to-earnings-growth ratio of 1.33 and a beta of 0.20. The firm’s 50-day simple moving average is $277.84 and its 200 day simple moving average is $241.96.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The firm had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. During the same period last year, the business posted $1.86 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, equities analysts forecast that AbbVie Inc. will post 13.98 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a $1.82 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. AbbVie’s dividend payout ratio is presently 119.10%.

AbbVie Profile

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Featured Articles

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.